Viewing nowCombinationSitagliptin 50/500 mg Tablet
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.

MFDS item code 202204573 · Approved 2022.12.21 · Insurance code 622804980
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes to effectively improve blood sugar control when taken alongside diet and exercise therapy. Sitagliptin and metformin work together to help maintain stable blood sugar levels. This can help manage diabetes more smoothly and has positive effects on the prevention of complications. Therefore, this medication is used for blood sugar control in type 2 diabetes.
In antidiabetic therapy, the dosage of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, or for patients in whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medication is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients in whom adequate glycemic control cannot be achieved with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their existing doses of sitagliptin and metformin. 3. Patients in whom adequate glycemic control cannot be achieved with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in treatment for type 2 diabetes mellitus may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other condition that may increase the risk of lactic acidosis, provided that the following dose adjustments are made. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin, and is primarily used for the treatment of type 2 diabetes. First, severe allergic reactions may occur during the use of this medication, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or lips occur, discontinue use immediately and consult a doctor. There is also a risk of acute pancreatitis, so if abdominal pain, vomiting, or severe abdominal discomfort occurs, notify healthcare professionals immediately. Metformin included in this medication may be dangerous for patients with poor kidney function, so regular kidney function tests should be performed, and this medication should not be taken in cases of significantly reduced kidney function. Particularly, this medication should be avoided in cases of acute conditions such as dehydration, severe infections, heart problems, or acute myocardial infarction, and it may be necessary to discontinue use for a period before any scheduled surgery. It is safe not to take this medication during pregnancy or breast-feeding. This medication can pose a risk of hypoglycemia, so when irregular meals, excessive exercise, or concurrent use with other blood sugar-lowering medications occur, blood sugar levels should be monitored carefully. It is advisable to avoid alcohol consumption during treatment, and patients with poor liver function should also refrain from taking this medication. Gastrointestinal side effects such as diarrhea, nausea, vomiting, abdominal discomfort, and headache may occur, and if symptoms are severe, consult a doctor. Long-term use of this medication may lower vitamin B12 levels, so regular blood tests should be performed and vitamin supplementation may be necessary if needed. Finally, it is important to maintain regular blood sugar tests and kidney function tests during treatment to ensure safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air ingress, and it is best kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication and prevent deterioration.
Light pink oval film-coated tablets
56 tablets/box [(14 tablets/PTP x 4)], 200 tablets/bottle, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.